This is important because, although various P-gp inhibitors have been shown to overcome cancer MDR, most of them are substrates of P-gp, and therefore they might cause adverse drug-drug interactions at P-gp in normal organs such as the kidney [25]. This evidence concerns the gene PGP and cancer.